Anti-tumor activity of elacestrant (RAD1901) in combination with alpelisib (BYL-719) in patient-derived xenograft models of ER plus breast cancer

被引：0
|
作者：
Sankaran, Banu
Garner, Fiona
Hattersley, Gary
Purandare, Dinesh
Bihani, Teeru
机构：
[1] Novartis, Cambridge, MA USA
[2] Radius Hlth, Waltham, MA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-04-14
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
    Bihani, Teeru
    Patel, Hitisha K.
    Arlt, Heike
    Tao, Nianjun
    Jiang, Hai
    Brown, Jeffrey L.
    Purandare, Dinesh M.
    Hattersley, Gary
    Garner, Fiona
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4793 - 4804
  • [2] Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER plus breast cancer models resistant to CDK4/6 inhibitors
    Patel, Hitisha K.
    Tao, Nianjun
    Lee, Kyung-Min
    Huerta, Mariela
    Arlt, Heike
    Mullarkey, Tara
    Troy, Steven
    Arteaga, Carlos L.
    Bihani, Teeru
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [3] Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
    Hitisha K. Patel
    Nianjun Tao
    Kyung-Min Lee
    Mariela Huerta
    Heike Arlt
    Tara Mullarkey
    Steven Troy
    Carlos L. Arteaga
    Teeru Bihani
    Breast Cancer Research, 21
  • [4] RAD1901 demonstrates anti-tumor activity in multiple models of ER-positive breast cancer treatment resistance
    Bihani, T.
    Arlt, H.
    Brechbuhl, H.
    Patel, H.
    Tao, N.
    Purandare, D. M.
    Hattersley, G.
    Kabos, P.
    Garner, F.
    CANCER RESEARCH, 2017, 77
  • [5] Elacestrant (RAD1901) demonstrates anti-tumor activity in models resistant to CDK4/6 inhibitors
    Patel, H.
    Tao, N.
    Arlt, H.
    Bihani, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model
    Arlt, Heike
    Garner, Fiona
    Bihani, Teeru
    CANCER RESEARCH, 2018, 78 (04)
  • [7] Anti-tumor activity of elacestrant (RAD1901) in models harboring ESR1 mutations resistant to standard of care therapies
    Patel, H.
    Tao, N.
    Arlt, H.
    Bihani, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] RAD1901, an orally available SERD, as an effective combination partner in ER plus breast cancer
    Bihani, Teeru
    Brown, Jeffrey L.
    Purandare, Dinesh M.
    Hattersley, Gary
    Garner, Fiona
    CANCER RESEARCH, 2016, 76
  • [9] EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER plus advanced breast cancer
    Bardia, Aditya
    Aftimos, Philippe
    Bihani, Teeru
    Anderson-Villaluz, Alfred T.
    Jung, JungAh
    Conlan, Maureen G.
    Kaklamani, Virginia G.
    FUTURE ONCOLOGY, 2019, 15 (28) : 3209 - 3218
  • [10] RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
    Garner, Fiona
    Shomali, Maysoun
    Paquin, Dotty
    Lyttle, C. Richard
    Hattersley, Gary
    ANTI-CANCER DRUGS, 2015, 26 (09) : 948 - 956
12345